Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 23, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 23, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$61.00 – $64.00Entry zone — fair-value band

$63.39Published — price the day we called it

$74.80Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$38.52Window close — end-of-window price, context only

What happened

Partial

Reached 7% of the predicted growth at its peak, without hitting the target.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+1.2%

peak, from the publication price

Window close

$38.52

end-of-window price, context only

Days to target

—

Window

January 23, 2026 – April 23, 2026

The thesis — published January 23, 2026

Predicted growth

+18%

over the measurement window

Target price

$74.80

the price the thesis aimed for

Entry zone

$61.00 – $64.00

the fair-value band we waited for

Price at publication

$63.39

published January 23, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

There is fresh positive news: many U.S. patients are starting the new oral Wegovy pill, which can lift sales and make analysts more optimistic in the short term. At the same time, a report about a generic version being cleared in India creates uncertainty about competition and pricing. The stock has run up, so buying on drops is safer than chasing it now; keep position sizes small until trading calms.

Primary drivers

Strong early U.S. uptake for oral Wegovy can boost short-term sentiment
Leading position in obesity drugs keeps investor focus on growth
India generic clearance raises competition and possible price pressure
Buying only on pullbacks helps control risk in volatile conditions

How it played out

NVO: target was never reached

Lyra published NVO on 2026-01-23 at 63.39, with expected growth of 18% and a target of 74.8. The thesis pointed to strong early U.S. uptake for oral Wegovy, Novo Nordisk's leading position in obesity drugs, possible pressure from India generic clearance, and a preference for buying on pullbacks in volatile conditions.

Inside the 2026-01-23 to 2026-04-23 window, the stock peaked at 64.16 on 2026-01-23, a 1.2% gain. It never reached 74.8. By the end of the window it was 38.52. The thesis missed.

What happened during the window

On February 3, 2026, Novo Nordisk reported fourth-quarter results and said it expected 2026 adjusted sales to fall by 5% to 13%. AP also reported during the window that U.S. regulators approved a 7.2-milligram higher-dose Wegovy shot, with U.S. pharmacy availability planned for April.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals